Treatment patterns and outcomes in patients with multiple myeloma in second relapse in Colombia (freedomm): a multicenter observational study - Takeaways - MDSpire

Treatment patterns and outcomes in patients with multiple myeloma in second relapse in Colombia (freedomm): a multicenter observational study

  • By

  • Guillermo Quintero

  • Sandra Aruachan

  • Jair Figueroa Emiliani

  • Kenny Galvez

  • Luis Antonio Salazar

  • Constanza Otero Venegas

  • Diana Buitrago

  • Humberto Martínez-Cordero

  • Juliana Saavedra

  • Maria Fernanda Vargas

  • July 1, 2026

  • 0 min

Share

  • 1

    The study included 84 Colombian patients with multiple myeloma who experienced a second relapse and initiated third-line therapy between 2013 and 2022.

  • 2

    The median age at diagnosis was 63.5 years, with bone disease and anemia being the most common presenting features among participants.

  • 3

    First-line therapy was primarily bortezomib-based, while second-line treatment shifted towards lenalidomide-based regimens.

  • 4

    In the third-line setting, the overall response rate was 47.1%, with a median overall survival of 27.5 months.

  • 5

    Treatment-emergent adverse events occurred in 11.9% of patients, predominantly moderate and mostly hematologic.

Original Source(s)

Treatment patterns and outcomes in patients with multiple myeloma in second relapse in Colombia (freedomm): a multicenter observational study

  • by Guillermo Quintero, Sandra Aruachan, Jair Figueroa Emiliani, Kenny Galvez, Luis Antonio Salazar, Constanza Otero Venegas, Diana Buitrago, Humberto Martínez-Cordero, Juliana Saavedra, Maria Fernanda Vargas

  • July 1, 2026

Related Content

The gut microbiota in colorectal cancer: role in cytokine regulation, intestinal immune barrier dysfunction

Robot-assisted laparoscopic resection of giant pelvic solitary fibrous tumor: a case report with literature review

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target